New drug regimen reduces toxicities in patients with renal cancer
Findings of a 7-year study revolutionized the standard protocol for patient management by reducing toxicities for patients with metastatic renal cell carcinoma (mRCC).
Diagnosis & Disease Information
Existing drug extends survival for patients with rare thymic carcinoma
Sunitinib, an agent approved for use in several cancers, could prove useful in treatment of thymic carcinoma when traditional chemotherapy fails.
Pazopanib tolerated best in kidney cancer study
A trial comparing pazopanib and sunitinib found pazopanib to have better safety and health-related quality-of-life profiles among persons with metastatic renal cell carcinoma.
Potential markers investigated for sunitinib response in patients with metastatic ccRCC
Markers in primary tumors such as CA9, CD31, CD34, and VEGFR1/2 might serve as predictors of a good response to sunitinib treatment in patients with metastatic clear cell renal carcinoma (ccRCC).
Sunitinib does not speed growth of renal cancer in humans
Animal studies have suggested that sunitinib may promote cancer growth and metastasis, but this does not appear to happen in humans.
Regorafenib prolongs survival in face of GI cancers
Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.
Targeted drug overcomes resistance in patients with rare sarcoma
Regorafenib, a new, targeted, oral drug, demonstrated the ability to control metastatic GIST, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies.
The role of sunitinib in the treatment of GIST
What is the role of sunitinib malate in the treatment of sarcomas?
How kidney cancer therapies could improve quality of life
Kidney cancer drugs in development could improve patients’ quality of life and allow more effective treatment, according to Professor Robert Hawkins of Manchester University.
- Loading...
Loading...
Loading... 
Loading...